Trials / Recruiting
RecruitingNCT06465433
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tafasitamab | Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols. |
Timeline
- Start date
- 2022-11-08
- Primary completion
- 2027-08-29
- Completion
- 2027-08-29
- First posted
- 2024-06-18
- Last updated
- 2025-12-10
Locations
5 sites across 5 countries: Hungary, Italy, South Korea, Spain, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06465433. Inclusion in this directory is not an endorsement.